Article
Multicenter, Real-World Observational Study of AVA Therapy Following ELT/HET Switching in Chinese Children with Persistent/Chronic Primary ITP
2025-03-27
Abstract excerpt
<title>Abstract</title> <p>Avatrombopag (AVA), a second-generation thrombopoietin receptor agonist (TPO-RA), has demonstrated efficacy in pediatric persistent/chronic immune thrombocytopenia (ITP). However, critical evidence gaps persist regarding treatment-switching strategies between TPO-RAs, particularly when transitioning from eltrombopag (ELT) or hetrombopag (HET) to AVA. This multicenter cohort study evalua...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8ffc0be1-7704-5203-9127-f19acde1d587
- DOI
- 10.21203/rs.3.rs-6187960/v1
